Clinical trial
Crestor Versus Placebo in Subjects With Heart Failure
NCT00206310 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00206310 |
|---|---|
| Title | Crestor Versus Placebo in Subjects With Heart Failure |
| Official title | Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized, Double-Blind, Placebo Controlled Phase III Study With Rosuvastatin in Subjects With Chronic Symptomatic Systolic Heart Failure |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Heart Failure |
| Intervention type | Drug |
| Interventions | CRESTOR |
| Enrollment | 5,013 |
| Start date | Sep 1, 2003 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Sep 21, 2005 |
| Last update posted | Nov 19, 2010 |
| Countries | Belgium, Bulgaria, Czechia, Denmark, Finland, France, Germany, Hungary, Ireland, Netherlands, Norway, Poland and 9 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: